BridgeBio Pharma, Inc. cash flow to debt ratio of -16.34% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

BridgeBio Pharma, Inc.'s free cash flow has increased -14.31% from $-521.66M last year to $-447.01M, signaling increasing performance

BridgeBio Pharma, Inc.'s debt to equity ratio is -0.01, signaling that the company spent its equity and risk bankruptcy.

BridgeBio Pharma, Inc.'s debt to equity ratio is -0.01, signaling that the company spent its equity and risk bankruptcy.

BridgeBio Pharma, Inc. has negative EBITDA, making leverage ratio unreliable

BridgeBio Pharma, Inc.'s interest coverage ratio of 219.05 indicates that earnings with good margin can cover interest payments on company debt

BridgeBio Pharma, Inc.'s profit margin has increased (-57.46%) in the last year from -241.44% to -102.70%, signaling increasing performance

BridgeBio Pharma, Inc.'s short-term assets of $753.68M exceed its short-term liabilities of $287.97M

BridgeBio Pharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BridgeBio Pharma, Inc.'s return on equity of 31.70%, is higher than 15.00%, indicating good performance

BridgeBio Pharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BridgeBio Pharma, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

BridgeBio Pharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

BridgeBio Pharma, Inc. has negative free cash flow, indicating cash burn

BridgeBio Pharma, Inc.'s yearly earnings has decreased 36.12% since last year from $-535.76M to $-729.31M, signaling decreasing performance

BridgeBio Pharma, Inc.'s yearly revenue has increased 126.26% since last year from $221.90M to $502.08M, signaling increasing performance

ROIC -263.40% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BridgeBio Pharma, Inc.'s 3-year revenue CAGR of 86.30% is positive, indicating growing revenue over the past 3 years

BridgeBio Pharma, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

BridgeBio Pharma, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

BridgeBio Pharma, Inc. has insufficient data to evaluate this check.

BridgeBio Pharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BridgeBio Pharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

BridgeBio Pharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BridgeBio Pharma, Inc. is overvalued relative to its fair value price of -325.00 based on Earnings Fair Value model

BridgeBio Pharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BridgeBio Pharma, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

BridgeBio Pharma, Inc. has a price-to-sales ratio of 24.39x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue